HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
News|Articles|August 27, 2026
Diagnosing and Treating Alzheimer Disease: August's Key Developments
Author(s)Jessica Walters
Recap Alzheimer disease updates from August.
Advertisement
Advertisement
Alzheimer disease research and care advanced on multiple fronts this August, from new blood-based and imaging diagnostics to early-phase therapeutic data and expert perspective on evolving clinical practice. This recap rounds up key developments, including FDA actions on diagnostic tools, emerging pipeline results, and clinical guidance on benzodiazepine use in older adults amid ongoing questions about dementia risk.
Related to this article
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Advertisement
Advertisement